Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

IRM claims GDIR ligands for the treatment of diabetes and obesity

Nov. 10, 2009

Tesofensine effects on weight lead to phase III investigation

Nov. 10, 2009

Bupropion improves hypoactive sexual desire disorder in women

Nov. 10, 2009

FDA grants priority review to Shire's NDA for velaglucerase alfa in Gaucher disease

Nov. 10, 2009

Dipeptidyl peptidase IV inhibitors claimed by Taiwanese scientists as antidiabetics

Nov. 9, 2009

Dong-A PharmTech starts phase III trials of udenafil in men with erectile dysfunction

Nov. 9, 2009

Weight loss seen in one-year studies of velneperit in obese subjects

Nov. 9, 2009

New 11beta-HSD1 inhibitors claimed by sanofi-aventis for the treatment of type 2 diabetes

Nov. 6, 2009

Enobia Pharma initiates phase II trial of ENB-0040 in hypophosphatasia

Nov. 6, 2009

Significant weight loss, diabetes onset delay with liraglutide in obese subjects

Nov. 6, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal
BioWorld
A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell...